Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 14, 2001 - Issue 3
Submit an article Journal homepage
136
Views
1
CrossRef citations to date
0
Altmetric
Articles

Provider and Health Care System Response to a Bioterrorist Attack

John D. MaloneCorrespondence[email protected]
, MD
Pages 224-230 | Published online: 11 Dec 2017

For Further Reading Anthrax

  • Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993;90: 2291–2294.
  • Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31: 347–382. [Pneumonia in the context of bioterrorism]
  • Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management—United States, 1998. MMWR Morb Mortal Wkly Rep 1999;48: 69–74.
  • English JF, Cundiff MY, Malone JD, Pfeiffer JA, Bell M, Steele L, Miller M. Bioterrorism readiness plan: a template for healthcare facilities. APIC Bioterrorism Task Force/CDC Hospital Infections Program Bioterrorism Working Group. Available at http://www.apic.org. Accessed April 13, 1999.
  • Friedlander A. Anthrax. In Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, US Department of the Army, 1997: 467–478.
  • Gold H. Anthrax: report of 117 cases. Arch Intern Med 1955;96: 387–396.
  • Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, Parker G, Perm TM, Russell PK, Tonat K. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999;281: 1737–1745.
  • Keim M, Kaufmann AF. Principles for emergency response to bioterrorism. Ann Emerg Med 1999;34: 177–182.
  • Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med 1986;181: 71–77.
  • Levy LM, Baker N, Meyer MP, Crosland P, Hampton J. Anthrax meningitis in Zimbabwe. Cent Afr J Med 1981;27: 101–104.
  • Lightfoot NF, Scott RJD, Turnbull BCB. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl 1990;68: 95–98.
  • Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266: 1202–1208.
  • Pile J, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. Arch Intern Med 1998;158: 429–434.
  • Richards CF, Burstein JL, Waeckerle JF, Hutson HR. Emergency physicians and biological terrorism. Ann Emerg Med 1999;34: 183–190.
  • Walker DH, Yampolska O, Grinberg LM. Death at Sverdlovsk: what have we learned? Am J Pathol 1994;144: 1135–1141.

Anthrax Vaccine

  • Anthrax vaccine adsorbed [package insert]. Lansing, Mich: Michigan Department of Public Health, 1987.
  • Brachman PS, Friedlander AM. Anthrax. In Plotkin SA, Mortimer EA, eds. Vaccines, 2nd ed. Philadelphia: WB Saunders Co, 1994: 729–739.
  • Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of human anthrax vaccine. Am J Public Health 1962;52: 632–645.
  • Broster MG, Hibbs SE. Protective efficacy of anthrax vaccines against aerosol challenge. Salisbury Med Bull Suppl 1990;68: 91–92.
  • Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe RJ, Howe GB, Mikesell P, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167: 1239–1243.
  • Ivins BE, Fellows PF, Pitt MLM, Estep JE, Welkos SL, Worsham PL, Friedlander AM. Efficacy of standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med Bull Suppl 1996;87: 125–126.
  • Pitt MLM, Ivins BE, Estep JE, Frachus J, Friedlander AM. Comparison of the efficacy of purified protection antigen and MDPH to protect non-human primates from inhalational anthrax. Salisbury Med Bull Suppl 1996:87: 130.
  • Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine 1991;9: 533–539.

Anthrax Pathogenesis

  • Fritz DL, Jaax NKI, Lawrence WB, Davis KJ, Pitt ML, Ezzell JW, Friedlander AM. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest 1995;73: 691–702.
  • Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci U S A 1993;90: 10198–10201.
  • Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A 1982;79: 3162–3166.
  • Lincoln RE, Fish DC. Anthrax toxin. In Montie TC, Kadis S, Aji SJ, eds. Microbial Toxins, vol. 3, Bacterial Protein Toxins. New York: Academic Press, 1970: 316–414.
  • Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bact 1957;73: 485–494.
  • Smith H, Keppie J. Observations on experimental anthrax: demonstration of a specific factor produced in vivo by Bacillus anthracis. Nature 1954;173: 869–870.

Anthrax Epidemiology

  • Carr EA, Rew R. Recovery of Bacillus anthracis from the nose and throat of apparently healthy workers. J Infect Dis 1957;169–171.
  • Dahlgren C, Buchanan LM, Decker HM, Freed SW, Philips CR, Brachman PS. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg 1960;72: 24–31.
  • Watson A, Keir D. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect 1994;133: 479–490.

Botulism

  • Franz D. Defense against toxin weapons. In Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, US Department of Army, 1997: 603–619.
  • Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response. A public health strategy for a global challenge. JAMA 1997;278: 433–435.
  • US Army Medical Research Institute of Infectious Diseases (USAMRIID).
  • Medical Defense Against Biological Warfare Agents [course text]. Fort Detrick, Md: USAMRIID, 1997.

Plague

  • Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399–411.
  • McGovern TW, Friedlander AM. Plague. In Zajtchuk R, Bellamy RF, eds. Te x t -book of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, US Department of the Army, 1997: 479–502.

Smallpox

  • Board WJ, Miller J. Smallpox stocks hidden, report says, Iraq, N. Korea, Russia cited by intelligence assessment. New York Times; reprinted in Cleveland Plain Dealer, June 13, 1999.
  • DeClercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 1987;8: 261–272.
  • Fenner F. Poxviruses. In Richman DD, Whitley RJ, Hayden FG, eds. Clinical Virology. New York: Churchill Livingstone, 1997: 357–367.
  • Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl T, Russell PK, Tonat K. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999;281: 2127–2137.
  • Huggins JW, Robertson M, Kefauver D, Laughlin C. Potential antiviral therapeutics for smallpox and other pox virus infections. Presented at the 11th International Meeting on Poxviruses and Iridovirus, May 4–9, 1996, Toledo, Spain.
  • Huggins JW, Smee D, Martinez MJ. Cidofovir, HPMPC treatment of monkeypox. Presented at the 11th Conference on Antiviral Research, April 5–10, 1998, San Diego, Calif.
  • McClain DJ. Smallpox. In Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, US Department of the Army, 1997: 539–559.
  • McEvoy GK, ed. Smallpox vaccine. AHFS Drug Information 2001. Bethesda, Md: American Society of Health-Systems Pharmacists, 2001.
  • Naesens L, Snoeck R, Andrei G, et al. HPMPC (cidofovir), PMEA (adefovir) and related acyclic-nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997;8: 1–23.

Quinolone Utilization

  • Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25: 1196–1204.
  • Doganay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991;23: 333–335.
  • Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use—safety report. Pediatr Infect Dis J 1997;16: 127–129.
  • Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000;31 (Suppl 2): S24–S28.
  • Kohlhepp SJ, Grunkemeir G, Leggett JE, Dworkin RJ, Slaughter SE, Gilbert DN. Phenotypic resistance of penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae after single and multiple in vitro exposures to ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin and trovafloxacin [abstract 97]. 38th Annual Meeting, Infectious Diseases Society of America, New Orleans, La, 2000.
  • Millchap JJ, Pestova EV, Noskin GA, Peterson LR. Evidence for the presence of non-PMRA multidrug transport proteins in Streptococcus pneumoniae [abstract 99]. 38th Annual Meeting, Infectious Diseases Society of America, New Orleans, La, 2000.
  • Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000;31 (Suppl 2): S35–S39.
  • Sabella C, Goldfarb J. Fluoroquinolone therapy in pediatrics: where we stand. Clin Pediatr (Phila) 1997;336: 445–448.
  • Warren R. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis J 1997;16: 118–122.

Psychological Response

  • Burgess JL, Kirk M, Borron SW, Cisek J. Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med 1999;34: 205–212.
  • DiGiovanni C Jr. Domestic terrorism with chemical or biological agents: psychiatric aspects. Am J Psychiatry 1999;156: 1500–1505.
  • Fullerton CS, Ursano RJ. Behavioral and psychological responses to chemical and biological warfare. Mil Med 1990;155: 54–59.
  • Holloway HC, Norwood AE, Fullerton CS, Engel CC Jr, Ursano RJ. The threat of biological weapons. Prophylaxis and mitigation of psychological and social consequences. JAMA 1997;278: 425–427.
  • Kline NA, Dow BM, Brown SA, Matloff JL. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Am J Psychiatry 1994;151: 621.
  • Klonoff DC. Chronic fatigue syndrome. Clin Infect Dis 1992;15: 812–823.
  • Malone JD, Paige-Dobson B, Ohl C, DiGiovanni C, Cunnion S, Roy MJ. Possibilities for unexplained chronic illnesses among reserve units deployed in Operation Desert Shield/Desert Storm. South Med J 1996;89: 1147–1155.
  • Michels RM, Marzuk PM. Progress in psychiatry. Part 2. Mood disorder. N Engl J Med 1993;329: 628–638.
  • North CS, Nixon SJ, Shariat S, Mallonee S, McMillin JC, Spitznagel EL, Smith EM. Psychiatric disorders among survivors of the Oklahoma City bombing. JAMA 1999;282: 755–762.
  • van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994;55: 517–522.

Emergency Response

  • Cieslak TJ, Christopher GW, Kortepeter MG, Rowe JR, Pavlin JA, Culpepper RC, Eitzen EM Jr. Immunization against potential biological warfare agents. Clin Infect Dis 2000;30: 843–850.
  • Crosby AW. America's Forgotten Pandemic. Cambridge, UK: Cambridge University Press, 1998.
  • Diamond J. Guns, Germs, and Steel, the Fates of Human Societies. New York: WW Norton, 1999.
  • Henderson DA. Weapons for the future. Lancet 1999;354 (Suppl S4): 64.
  • Higgins JA, Ibrahim MS, Knauert FK, Ludwig GV, Kijek TM, Ezzell JW, Courtney BC, Henchal EA. Sensitive and rapid identification of biological threat agents. Ann N Y Acad Sci 1999;894: 130–148.
  • Hood E. Chemical and biological weapons: new questions, new answers. Environ Health Perspect 1999;107: 931–932.
  • Inglesby T, Grossman R, O'Toole T. A plague on your city: observations from TOPOFF. Clin Infect Dis 2001;32: 436–445.
  • Macintyre AG, Christopher GW, Eitzen E Jr, Gum R, Weir S, DeAtley C, Tonat K, Barbera JA. Weapons of mass destruction events with contaminated casualties: effective planning for health care facilities. JAMA 2000;283: 242–249.
  • Olson KB. Aum Shinrikyo: once and future threat? Emerg Infect Dis 1999;5: 513–516.
  • Steffan R, Melling J, Woodall JP, Rollin RH, Lang RH, Luthy R, Waldvogel A. Preparation for emergency relief after biological warfare. J Infect 1997;34: 127–132.
  • Waeckerle JF. Domestic preparedness for events involving weapons of mass destruction. JAMA 2000;283: 252–254.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.